Tibet Weixinkang Medicine Co., Ltd. (SHA:603676)
China
· Delayed Price · Currency is CNY 10.60
0.00 (0.00%)
Apr 30, 2026, 3:00 PM CST
Tibet Weixinkang Medicine Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Market Capitalization | 4,583 | 4,548 | 4,330 | 4,539 | 6,928 | 4,051 | Upgrade
|
| Market Cap Growth | 3.04% | 5.04% | -4.60% | -34.48% | 71.03% | 6.52% | Upgrade
|
| Enterprise Value | 3,542 | 3,539 | 3,282 | 3,710 | 6,150 | 3,412 | Upgrade
|
| Last Close Price | 10.60 | 10.52 | 9.67 | 9.64 | 14.47 | 8.30 | Upgrade
|
| PE Ratio | 21.15 | 19.53 | 17.59 | 21.21 | 39.15 | 42.23 | Upgrade
|
| PS Ratio | 3.94 | 4.01 | 3.33 | 3.43 | 4.95 | 3.92 | Upgrade
|
| PB Ratio | 2.97 | 3.08 | 3.13 | 3.39 | 5.68 | 3.80 | Upgrade
|
| P/TBV Ratio | 3.01 | 3.13 | 3.16 | 3.48 | 5.79 | 3.84 | Upgrade
|
| P/FCF Ratio | 33.34 | 44.76 | 13.76 | 26.65 | 41.12 | 35.20 | Upgrade
|
| P/OCF Ratio | 20.55 | 24.51 | 11.62 | 18.82 | 28.14 | 23.73 | Upgrade
|
| EV/Sales Ratio | 3.05 | 3.12 | 2.52 | 2.81 | 4.40 | 3.30 | Upgrade
|
| EV/EBITDA Ratio | 11.88 | 11.64 | 12.23 | 19.75 | 32.23 | 27.40 | Upgrade
|
| EV/EBIT Ratio | 14.20 | 13.65 | 14.78 | 25.58 | 39.80 | 36.72 | Upgrade
|
| EV/FCF Ratio | 25.77 | 34.83 | 10.43 | 21.79 | 36.51 | 29.64 | Upgrade
|
| Debt / Equity Ratio | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Debt / EBITDA Ratio | 0.04 | 0.04 | 0.02 | 0.04 | 0.03 | 0.04 | Upgrade
|
| Debt / FCF Ratio | 0.09 | 0.11 | 0.02 | 0.05 | 0.03 | 0.04 | Upgrade
|
| Net Debt / Equity Ratio | -0.67 | -0.66 | -0.73 | -0.66 | -0.66 | -0.66 | Upgrade
|
| Net Debt / EBITDA Ratio | -3.54 | -3.19 | -3.78 | -4.72 | -4.20 | -5.67 | Upgrade
|
| Net Debt / FCF Ratio | -7.57 | -9.56 | -3.22 | -5.21 | -4.75 | -6.14 | Upgrade
|
| Asset Turnover | 0.60 | 0.61 | 0.72 | 0.77 | 0.89 | 0.72 | Upgrade
|
| Inventory Turnover | 8.76 | 8.60 | 15.05 | 18.37 | 24.34 | 22.67 | Upgrade
|
| Quick Ratio | 3.31 | 3.21 | 2.79 | 2.73 | 2.50 | 2.16 | Upgrade
|
| Current Ratio | 3.74 | 3.70 | 3.08 | 3.04 | 2.77 | 2.41 | Upgrade
|
| Return on Equity (ROE) | 14.37% | 16.27% | 18.06% | 16.71% | 15.47% | 9.35% | Upgrade
|
| Return on Assets (ROA) | 8.10% | 8.71% | 7.64% | 5.27% | 6.11% | 4.07% | Upgrade
|
| Return on Invested Capital (ROIC) | 39.73% | 48.58% | 47.92% | 32.94% | 38.42% | 20.19% | Upgrade
|
| Return on Capital Employed (ROCE) | 15.70% | 17.10% | 15.60% | 10.50% | 12.30% | 8.60% | Upgrade
|
| Earnings Yield | 4.73% | 5.12% | 5.68% | 4.71% | 2.55% | 2.37% | Upgrade
|
| FCF Yield | 3.00% | 2.23% | 7.27% | 3.75% | 2.43% | 2.84% | Upgrade
|
| Dividend Yield | 3.08% | - | 3.54% | 2.96% | 1.62% | 1.93% | Upgrade
|
| Payout Ratio | 72.58% | 70.19% | 72.25% | 45.72% | 38.80% | 41.90% | Upgrade
|
| Buyback Yield / Dilution | -0.61% | 0.15% | -0.90% | 0.83% | -3.50% | 0.08% | Upgrade
|
| Total Shareholder Return | 2.47% | 0.15% | 2.64% | 3.79% | -1.88% | 2.00% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.